A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research

Ping Chen¹  Jun Xie¹  Guangyao Li¹  Xiaobiao Zhao¹  Yi Kuang¹  Dong Wei¹  Hongxu Chen¹  Bo Zhou¹ 

[1] Department of Hepatobiliary Surgery, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, China

关键词: JAK2/Stat3;    miR-219;    Hepatocellular carcinoma;    SMC4;   

Others  :  833724
DOI  :  10.1186/1756-9966-33-55

 received in 2014-04-01, accepted in 2014-06-24,  发布年份 2014

【 摘 要 】

Background

To understand the involvement of structural maintenance of chromosome 4 (SMC4) in the development and progression of hepatocellular carcinoma (HCC).

Methods

Real-time quantitative PCR and Western Blotting were applied to measure the expression of SMC4 in HCC samples and cell lines. The tumor-promoting effect of SMC4 was determined by WST-1, soft agar colony formation, cell motility and invasion assays. The SMC4 target signal pathway was identified by luciferase reporter and real-time quantitative PCR assays.

Results

The upregulation of SMC4 was frequently detected in HCC samples and cell lines. Functional assays demonstrated that SMC4 could effectively promote tumor cell growth rate, colony formation in soft agar, wound-healing and invasion. Further studies showed that increased miR-219 levels caused a significant decrease in the SMC4 expression, and SMC4 inhibitor downregulated JAK2/Stat3 expression at both the mRNA and protein levels.

Conclusions

Our findings provide new insight into SMC4 function and the mechanisms of growth and invasion of HCC.

【 授权许可】

   
2014 Zhou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [2]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [3]Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM: Role of the microenvironment in the pathogenesis and treatment o hepatocellular carcinoma. Gastroenterology 2013, 144:512-527.
• [4]Dibisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004, 1275:104-107.
• [5]Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L: Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 2013, 32:21.
• [6]Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH: Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010, 46:744-751.
• [7]Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM: MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011, 140:1618-1628.
• [8]Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
• [9]Zucman-Rossi J, Laurent-Puig P: Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics 2007, 8:997-1003.
• [10]Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010, 30:35-51.
• [11]Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM: A novel GSK-3 beta–C/EBP alpha–miR-122–insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010, 52:1702-1712.
• [12]Xiao Q, Qu K, Wang C, Kong Y, Liu C, Jiang D, Saiyin H, Jia F, Ni C, Chen T, Zhang Y, Zhang P, Qin W, Sun Q, Wang H, Yi Q, Liu J, Huang H, Yu L: HDGF-related protein-3 is required for anchorage-independent survival and chemoresistanc in hepatocellular carcinomas. Gut 2013, 62:440-451.
• [13]Xia L, Huang W, Tian D, Chen Z, Zhang L, Li Y, Hu H, Liu J, Chen Z, Tang G, Dou J, Sha S, Xu B, Liu C, Ma J, Zhang S, Li M, Fan D, Nie Y, Wu K: ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Oncogene 2014, 33:1395-406.
• [14]Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW: Signaling through the JAK / STAT pathway, recent advances and future challenges. Gene 2002, 285:1-24.
• [15]Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D, Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett 2012, 586:884-891.
• [16]Huynh H: Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010, 80:550-560.
• [17]Zhou B, Yuan T, Liu M, Liu H, Xie J, Shen Y, Chen P: Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de- differentiation, advanced stage and vascular invasion of primary liver cancer. Oncol Rep 2013, 28:1263-1268.
• [18]Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR, Guan XY: MicroRNA −375 inhibits tumour growth and metastas in oesophageal squamous cell carcinoma through epressing insulin-like growth factor 1 receptor. Gut 2013, 61:33-42.
• [19]Kong KL, Kwong DL, Fu L, Chan TH, Chen L, Liu H, Li Y, Zhu YH, Bi J, Qin YR, Law SY, Guan XY: Characterization of a candidate tumor suppresso gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res 2010, 70:8832-8841.
• [20]McDowall MD, Scott MS, Barton GJ: PIPs: Human protein-protein interactions prediction database. Nucleic Acids Res 2009, 37:651-656.
• [21]Yellaboina S, Tasneem A, Zaykin DV, Raghavachari B, Jothi R: DOMINE: A comprehensive collection of known and predicted domain-domain interactions. Nucleic Acids Res 2011, 39:730-735.
• [22]Losada A, Hirano T: Dynamic molecular linkers of the genome: the first decade of SMC proteins. Genes Dev 2005, 19:1269-1287.
• [23]Griese JJ, Hopfner KP: Structure and DNA-binding activity of the Pyrococcus furiosus SMC protein hinge domain. Proteins 2011, 79:558-568.
• [24]Hirano T: Condensins: Organizing and segregating the genome. Curr Biol 2005, 15:265-275.
• [25]Freeman L, Aragon-Alcaide L, Strunnikov A: The condensing complex governs chromosome condensation and mitotic transmission of rDNA. J Cell Biol 2000, 149:811-824.
• [26]Yu L, Peña Castillo L, Mnaimneh S, Hughes TR, Brown GW: A survey of essential gene function in the yeast cell division cycle. Mol Biol Cell 2006, 17:4736-4747.
• [27]Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC: Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane- resistant breast cancer cells. Breast Cancer Res Treat 2011, 125:55-63.
• [28]Lei H, Zou D, Li Z, Luo M, Dong L, Wang B, Yin H, Ma Y, Liu C, Wang F, Zhang J, Yu J, Li Y: MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation. PLoS One 2013, 8:e60369.
• [29]Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008, 14:2588-2592.
• [30]Dugas JC, Cuellar TL, Scholze A, Ason B, Ibrahim A, Emery B, Zamanian JL, Foo LC, McManus MT, Barres BA: Dicer1 andmiR-219 Are requiredfor normal oligodendrocyte differentiation andmyelination. Neuron 2010, 65:597-611.
• [31]Ho M, Kim H: Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 2011, 47:333-338.
• [32]Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
• [33]Yu H, Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
• [34]Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
• [35]Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002, 21:7611-7618.
• [36]Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
• [37]Liu Y, Liu A, Li H, Li C, Lin J: Celecoxib inhibits interleukin-6/interleukin-6 receptor- induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res 2011, 4:1296-1305.
• [38]Morita Y, Naka T, Kawazoe Y, Fujimoto M, Narazaki M, Nakagawa R, Fukuyama H, Nagata S, Kishimoto T: Signals transducers and activators of transcription (STAT) -induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc Natl Acad. Sci USA 2000, 97:5405-5410.
• [39]Gamero AM, Young HA, Wiltrout RH: Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004, 5:111-112.
• [40]Subramaniam A, Anmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G: Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 1835, 2013:46-60.
• [41]Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L: Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest 2013, 123:2576-2589.
• [42]Wen Z, Darnell JE Jr: Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 1997, 25:2062-2067.